Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719030 | 0.86 | MAPT (0.71) | MAPTALDH1A1SIRT6HSD11B1LMNA | |
| Ammonia Solution, Strong SCHEMBL27607340 | 0.84 | MAPT (0.69) | MAPTALDH1A1SIRT6HSD11B1LMNA | |
| SCHEMBL6151230 | 0.83 | SIRT6 (0.81) | MAPTALDH1A1SIRT6LMNASMN1; SMN2 | |
| SCHEMBL15271381 | 0.83 | SIRT6 (0.81) | MAPTALDH1A1SIRT6LMNASMN1; SMN2 | |
| SCHEMBL3051184 | 0.82 | MAPT (1.00) | MAPTALDH1A1SIRT6HSD11B1LMNA | |
| SCHEMBL22495982 | 0.81 | SIRT6 (0.68) | MAPTALDH1A1SIRT6HSD11B1LMNA | |
| SCHEMBL374222 | 0.81 | SIRT6 (0.68) | MAPTALDH1A1SIRT6LMNASMN1; SMN2 | |
| SCHEMBL25797013 | 0.81 | SIRT6 (0.59) | MAPTALDH1A1SIRT6LMNASMN1; SMN2 | |
| SCHEMBL18463446 | 0.79 | SIRT6 (0.60) | MAPTALDH1A1SIRT6LMNASMN1; SMN2 | |
| SCHEMBL12240580 | 0.78 | SIRT6 (0.74) | MAPTALDH1A1SIRT6LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339145-B2 | Synthesis of cerdulatinib | ALEXION PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210147392-A1 | SYNTHESIS OF CERDULATINIB | ALEXION PHARMACEUTICALS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10851087-B2 | Synthesis of cerdulatinib | PORTOLA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190337930-A1 | SYNTHESIS OF CERDULATINIB | ALEXION PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
| US-20090170851-A1 | Chroman Compounds | BERNSTEIN PETER | 2009-07-02 | — | — | US | disclosed |
| EP-1945624-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | Astra Zeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053093-A1 | CHROMAN COMPOUNDS AS 5 HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170851-A1 | Chroman Compounds | CYP3A43, CYP2C9, CYP2C8 | MAPT 3013/4885ALDH1A1 1638/4885SIRT6 3453/4885 |
| US-20210147392-A1 | SYNTHESIS OF CERDULATINIB | JAK2, DCK, CERS2 | MAPT 3748/4885ALDH1A1 2168/4885SIRT6 1624/4885 |
| US-20070185107-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | MAPT 3013/4885ALDH1A1 1638/4885SIRT6 3453/4885 |
| US-20190337930-A1 | SYNTHESIS OF CERDULATINIB | JAK2, DCK, CERS2 | MAPT 3748/4885ALDH1A1 2168/4885SIRT6 1624/4885 |
| US-10851087-B2 | Synthesis of cerdulatinib | JAK2, DCK, CERS2 | MAPT 3748/4885ALDH1A1 2168/4885SIRT6 1624/4885 |
| US-11339145-B2 | Synthesis of cerdulatinib | JAK2, DCK, CERS2 | MAPT 3748/4885ALDH1A1 2168/4885SIRT6 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.